Aurinia Pharmaceuticals Net Income

The latest net income for AUPH is $310M as of June 2026. That compares with $61M in the prior-year period — up 418.0% year over year. That is below the Healthcare sector average of $16B. Investors often review this figure alongside Aurinia Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, AUPH's net income moved from $61M to $310M — a 418.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Aurinia Pharmaceuticals's operating scale or balance-sheet position.

Against Healthcare companies, AUPH currently prints $310M for net income, while the sector average sits near $16B. That is roughly 98.1% below the sector mean. Large gaps often invite a closer look at Aurinia Pharmaceuticals's growth, margins, and balance sheet.

A net income figure of $310M for AUPH is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $16B. Explore the charts below for those layers of context.

After noting AUPH's net income ($310M), review year-over-year change from $61M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.